Laura James
Concepts (546)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acetaminophen | 59 | 2023 | 349 | 12.380 |
Why?
| Analgesics, Non-Narcotic | 25 | 2021 | 140 | 5.160 |
Why?
| Drug Overdose | 15 | 2019 | 154 | 3.080 |
Why?
| Liver | 23 | 2020 | 1225 | 2.930 |
Why?
| Hepatocytes | 15 | 2018 | 214 | 2.410 |
Why?
| Liver Failure, Acute | 11 | 2018 | 64 | 2.200 |
Why?
| Liver Regeneration | 9 | 2019 | 57 | 2.070 |
Why?
| Alanine Transaminase | 17 | 2023 | 151 | 1.370 |
Why?
| MicroRNAs | 4 | 2020 | 386 | 1.320 |
Why?
| Cytochrome P-450 CYP2E1 | 4 | 2020 | 105 | 1.220 |
Why?
| Acetylcysteine | 13 | 2019 | 118 | 1.220 |
Why?
| Mitochondria, Liver | 10 | 2015 | 86 | 1.180 |
Why?
| Adolescent | 44 | 2022 | 6897 | 1.170 |
Why?
| Male | 82 | 2022 | 27334 | 1.150 |
Why?
| Cytochrome P-450 CYP3A | 3 | 2020 | 82 | 1.100 |
Why?
| Child | 41 | 2023 | 7341 | 1.040 |
Why?
| Oxidative Stress | 12 | 2023 | 958 | 1.040 |
Why?
| Proton Pump Inhibitors | 6 | 2018 | 84 | 1.000 |
Why?
| Chromatography, High Pressure Liquid | 10 | 2016 | 377 | 0.960 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2012 | 60 | 0.910 |
Why?
| Humans | 99 | 2023 | 54284 | 0.910 |
Why?
| Child, Preschool | 28 | 2022 | 4147 | 0.910 |
Why?
| Attitude | 2 | 2021 | 82 | 0.910 |
Why?
| Asthma | 4 | 2022 | 293 | 0.910 |
Why?
| Cytokines | 8 | 2012 | 676 | 0.900 |
Why?
| Proteins | 4 | 2016 | 376 | 0.840 |
Why?
| Vitamin D Deficiency | 1 | 2022 | 53 | 0.830 |
Why?
| Animals | 41 | 2023 | 14385 | 0.820 |
Why?
| Female | 60 | 2021 | 28441 | 0.800 |
Why?
| Health Facilities | 1 | 2021 | 39 | 0.770 |
Why?
| Inflammation | 3 | 2020 | 674 | 0.720 |
Why?
| Cytochrome P-450 CYP1A2 | 4 | 2020 | 46 | 0.720 |
Why?
| Health Services Accessibility | 2 | 2021 | 432 | 0.720 |
Why?
| Naphthalenes | 9 | 2018 | 126 | 0.720 |
Why?
| Indoles | 9 | 2018 | 289 | 0.710 |
Why?
| Liver Diseases | 4 | 2023 | 87 | 0.700 |
Why?
| Vascular Endothelial Growth Factor A | 3 | 2011 | 230 | 0.690 |
Why?
| Mice | 29 | 2023 | 6413 | 0.690 |
Why?
| Bronchoconstriction | 1 | 2019 | 10 | 0.690 |
Why?
| Cysteine | 6 | 2017 | 62 | 0.680 |
Why?
| 2-Pyridinylmethylsulfinylbenzimidazoles | 4 | 2018 | 21 | 0.660 |
Why?
| Aspartate Aminotransferases | 8 | 2015 | 57 | 0.650 |
Why?
| Mitochondria | 2 | 2020 | 489 | 0.650 |
Why?
| Bronchodilator Agents | 1 | 2019 | 74 | 0.630 |
Why?
| Radius | 1 | 2018 | 27 | 0.630 |
Why?
| Immunoassay | 1 | 2016 | 31 | 0.580 |
Why?
| Aryl Hydrocarbon Hydroxylases | 4 | 2014 | 70 | 0.580 |
Why?
| Serum | 1 | 2016 | 39 | 0.570 |
Why?
| Gastroesophageal Reflux | 4 | 2018 | 49 | 0.570 |
Why?
| Anti-Bacterial Agents | 6 | 2023 | 820 | 0.550 |
Why?
| Dose-Response Relationship, Drug | 12 | 2019 | 1476 | 0.550 |
Why?
| Cystic Fibrosis | 1 | 2018 | 157 | 0.530 |
Why?
| Infant | 21 | 2022 | 3817 | 0.530 |
Why?
| Lung | 1 | 2019 | 507 | 0.520 |
Why?
| Mice, Inbred C57BL | 15 | 2019 | 1999 | 0.520 |
Why?
| HMGB1 Protein | 2 | 2021 | 17 | 0.520 |
Why?
| Keratin-18 | 2 | 2021 | 15 | 0.520 |
Why?
| Reactive Nitrogen Species | 3 | 2015 | 37 | 0.520 |
Why?
| Proliferating Cell Nuclear Antigen | 4 | 2019 | 82 | 0.520 |
Why?
| Bile Acids and Salts | 1 | 2015 | 76 | 0.510 |
Why?
| Young Adult | 16 | 2021 | 4318 | 0.510 |
Why?
| Mass Spectrometry | 4 | 2014 | 313 | 0.510 |
Why?
| Mice, Inbred Strains | 7 | 2019 | 198 | 0.490 |
Why?
| Tyrosine | 4 | 2007 | 137 | 0.490 |
Why?
| Isoniazid | 1 | 2014 | 30 | 0.480 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 142 | 0.470 |
Why?
| Carnitine | 1 | 2014 | 86 | 0.460 |
Why?
| Autoantibodies | 1 | 2014 | 132 | 0.460 |
Why?
| Trifluoperazine | 1 | 2012 | 9 | 0.440 |
Why?
| Disease Models, Animal | 7 | 2020 | 1639 | 0.440 |
Why?
| Antivenins | 1 | 2012 | 12 | 0.430 |
Why?
| Crotalid Venoms | 1 | 2012 | 12 | 0.430 |
Why?
| Anti-Ulcer Agents | 3 | 2007 | 20 | 0.430 |
Why?
| Sensitivity and Specificity | 9 | 2016 | 923 | 0.430 |
Why?
| Immunoglobulin Fragments | 1 | 2012 | 19 | 0.430 |
Why?
| Snake Bites | 1 | 2012 | 19 | 0.430 |
Why?
| Viperidae | 1 | 2012 | 10 | 0.430 |
Why?
| Tomography, X-Ray Computed | 1 | 2018 | 1213 | 0.420 |
Why?
| Echinomycin | 1 | 2011 | 7 | 0.420 |
Why?
| Hospitalization | 4 | 2017 | 705 | 0.400 |
Why?
| Spider Venoms | 1 | 2011 | 6 | 0.400 |
Why?
| Half-Life | 6 | 2019 | 92 | 0.400 |
Why?
| Cannabinoids | 5 | 2013 | 108 | 0.400 |
Why?
| Hypersensitivity | 1 | 2012 | 82 | 0.400 |
Why?
| Phosphoric Diester Hydrolases | 1 | 2011 | 29 | 0.390 |
Why?
| Necrosis | 6 | 2019 | 208 | 0.390 |
Why?
| Enzyme Inhibitors | 5 | 2019 | 446 | 0.380 |
Why?
| Indocyanine Green | 1 | 2010 | 39 | 0.380 |
Why?
| Adult | 19 | 2023 | 14207 | 0.370 |
Why?
| Macrolides | 3 | 2022 | 17 | 0.360 |
Why?
| Prospective Studies | 11 | 2021 | 2604 | 0.350 |
Why?
| Methamphetamine | 3 | 2013 | 233 | 0.340 |
Why?
| Metabolomics | 3 | 2015 | 149 | 0.340 |
Why?
| Triazoles | 3 | 2022 | 120 | 0.340 |
Why?
| Central Nervous System Stimulants | 3 | 2013 | 255 | 0.330 |
Why?
| Middle Aged | 15 | 2021 | 13088 | 0.330 |
Why?
| Protein Binding | 5 | 2017 | 736 | 0.320 |
Why?
| Homeostasis | 3 | 2020 | 223 | 0.320 |
Why?
| Chemokines | 2 | 2010 | 96 | 0.320 |
Why?
| Research Subjects | 2 | 2019 | 58 | 0.310 |
Why?
| Chemokine CCL2 | 2 | 2005 | 78 | 0.310 |
Why?
| Community-Based Participatory Research | 2 | 2021 | 209 | 0.310 |
Why?
| Imines | 3 | 2019 | 15 | 0.310 |
Why?
| Poisoning | 2 | 2006 | 31 | 0.300 |
Why?
| Benzoquinones | 3 | 2019 | 33 | 0.300 |
Why?
| Area Under Curve | 8 | 2019 | 205 | 0.300 |
Why?
| Tandem Mass Spectrometry | 6 | 2018 | 248 | 0.290 |
Why?
| Models, Biological | 6 | 2018 | 823 | 0.290 |
Why?
| Interleukin-8 | 3 | 2012 | 97 | 0.290 |
Why?
| Interleukin-6 | 3 | 2012 | 315 | 0.290 |
Why?
| Burns, Chemical | 1 | 2006 | 6 | 0.290 |
Why?
| Caustics | 1 | 2006 | 4 | 0.290 |
Why?
| Hypoxia-Inducible Factor 1 | 1 | 2006 | 7 | 0.280 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 25 | 0.280 |
Why?
| Pandemics | 2 | 2022 | 579 | 0.280 |
Why?
| Signal Transduction | 5 | 2019 | 1753 | 0.280 |
Why?
| Cell Death | 4 | 2020 | 223 | 0.280 |
Why?
| Cross-Sectional Studies | 3 | 2022 | 1693 | 0.270 |
Why?
| Antidotes | 4 | 2011 | 33 | 0.270 |
Why?
| Infant, Premature | 4 | 2016 | 335 | 0.270 |
Why?
| Liver Function Tests | 2 | 2002 | 43 | 0.270 |
Why?
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2005 | 40 | 0.260 |
Why?
| Gene Expression Regulation | 3 | 2016 | 1062 | 0.260 |
Why?
| Peroxynitrous Acid | 2 | 2007 | 51 | 0.260 |
Why?
| Reactive Oxygen Species | 3 | 2015 | 491 | 0.260 |
Why?
| Predictive Value of Tests | 5 | 2016 | 1048 | 0.250 |
Why?
| Infant, Newborn | 10 | 2018 | 2907 | 0.250 |
Why?
| Arkansas | 5 | 2022 | 2100 | 0.250 |
Why?
| Cytochrome P-450 Enzyme System | 3 | 2015 | 192 | 0.250 |
Why?
| Ion Channels | 1 | 2004 | 75 | 0.240 |
Why?
| Glutathione | 4 | 2023 | 330 | 0.240 |
Why?
| Up-Regulation | 4 | 2018 | 508 | 0.240 |
Why?
| Blood Pressure Monitoring, Ambulatory | 2 | 2015 | 40 | 0.240 |
Why?
| Gastric Acidity Determination | 1 | 2003 | 11 | 0.240 |
Why?
| Biotransformation | 4 | 2015 | 100 | 0.240 |
Why?
| Immunohistochemistry | 3 | 2012 | 1089 | 0.240 |
Why?
| Aminoglycosides | 1 | 2023 | 22 | 0.240 |
Why?
| Chromatography, Liquid | 6 | 2018 | 243 | 0.230 |
Why?
| Glucuronosyltransferase | 3 | 2017 | 157 | 0.220 |
Why?
| Administration, Oral | 7 | 2018 | 459 | 0.220 |
Why?
| Granzymes | 2 | 2020 | 13 | 0.210 |
Why?
| Pneumonia, Bacterial | 1 | 2022 | 26 | 0.210 |
Why?
| Membrane Glycoproteins | 1 | 2003 | 269 | 0.210 |
Why?
| Pilot Projects | 4 | 2021 | 808 | 0.210 |
Why?
| Community-Acquired Infections | 1 | 2022 | 42 | 0.210 |
Why?
| Digestive System | 1 | 2002 | 19 | 0.210 |
Why?
| Designer Drugs | 2 | 2013 | 28 | 0.210 |
Why?
| Vitamins | 1 | 2022 | 72 | 0.210 |
Why?
| Gastrointestinal Agents | 1 | 2002 | 36 | 0.210 |
Why?
| Vitamin D | 1 | 2022 | 101 | 0.210 |
Why?
| Phosphatidic Acids | 2 | 2019 | 8 | 0.210 |
Why?
| Obesity | 2 | 2022 | 1202 | 0.210 |
Why?
| Photography | 1 | 2021 | 39 | 0.200 |
Why?
| Anti-Infective Agents | 2 | 2013 | 110 | 0.200 |
Why?
| Dried Blood Spot Testing | 2 | 2018 | 5 | 0.200 |
Why?
| Metabolic Clearance Rate | 5 | 2018 | 75 | 0.200 |
Why?
| Microsomes, Liver | 4 | 2015 | 214 | 0.200 |
Why?
| United States | 7 | 2022 | 5217 | 0.200 |
Why?
| Gastrointestinal Diseases | 1 | 2002 | 126 | 0.190 |
Why?
| Oxidation-Reduction | 6 | 2023 | 382 | 0.190 |
Why?
| Bayes Theorem | 3 | 2012 | 123 | 0.190 |
Why?
| Aged | 6 | 2021 | 10054 | 0.190 |
Why?
| Hydroxyurea | 1 | 2020 | 29 | 0.190 |
Why?
| Polymorphism, Genetic | 2 | 2018 | 193 | 0.180 |
Why?
| Histamine H2 Antagonists | 3 | 2005 | 23 | 0.180 |
Why?
| Aged, 80 and over | 4 | 2021 | 3431 | 0.180 |
Why?
| Heart Arrest | 1 | 2022 | 159 | 0.180 |
Why?
| Hepatic Veno-Occlusive Disease | 1 | 2019 | 10 | 0.180 |
Why?
| Substance-Related Disorders | 3 | 2022 | 671 | 0.180 |
Why?
| Statistics, Nonparametric | 2 | 2011 | 232 | 0.180 |
Why?
| Cell Line | 3 | 2017 | 1153 | 0.170 |
Why?
| Prothrombin Time | 3 | 2005 | 19 | 0.170 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2022 | 596 | 0.170 |
Why?
| Lipids | 1 | 2020 | 178 | 0.170 |
Why?
| Glycerol-3-Phosphate O-Acyltransferase | 1 | 2019 | 5 | 0.170 |
Why?
| Recombinant Proteins | 4 | 2018 | 569 | 0.170 |
Why?
| ortho-Aminobenzoates | 1 | 2019 | 9 | 0.170 |
Why?
| Binding Sites | 2 | 2017 | 440 | 0.170 |
Why?
| Respiratory Hypersensitivity | 1 | 2019 | 18 | 0.170 |
Why?
| Carbachol | 1 | 2019 | 33 | 0.170 |
Why?
| Liver Cirrhosis | 1 | 2021 | 216 | 0.170 |
Why?
| Diagnosis, Differential | 3 | 2015 | 1136 | 0.170 |
Why?
| Mice, Knockout | 4 | 2011 | 926 | 0.170 |
Why?
| Organ Culture Techniques | 1 | 2019 | 53 | 0.170 |
Why?
| Child, Hospitalized | 1 | 2019 | 34 | 0.170 |
Why?
| Stress, Physiological | 1 | 2020 | 194 | 0.170 |
Why?
| Disclosure | 1 | 2019 | 39 | 0.170 |
Why?
| Cannabidiol | 1 | 2019 | 35 | 0.170 |
Why?
| Drug Administration Schedule | 4 | 2021 | 401 | 0.170 |
Why?
| Hepatitis, Viral, Human | 1 | 2018 | 6 | 0.170 |
Why?
| Bacterial Infections | 2 | 2017 | 105 | 0.170 |
Why?
| Case-Control Studies | 3 | 2018 | 1228 | 0.160 |
Why?
| Oropharynx | 2 | 2009 | 14 | 0.160 |
Why?
| Time Factors | 5 | 2013 | 3213 | 0.160 |
Why?
| Body Weight | 3 | 2018 | 578 | 0.160 |
Why?
| Ampicillin | 1 | 2018 | 6 | 0.160 |
Why?
| Phosphatidate Phosphatase | 1 | 2018 | 11 | 0.160 |
Why?
| Research Personnel | 1 | 2019 | 69 | 0.160 |
Why?
| Albuterol | 1 | 2019 | 58 | 0.160 |
Why?
| HSP72 Heat-Shock Proteins | 1 | 2018 | 8 | 0.160 |
Why?
| Hepatitis, Autoimmune | 1 | 2018 | 29 | 0.160 |
Why?
| Protein Biosynthesis | 2 | 2017 | 273 | 0.160 |
Why?
| Health Status Disparities | 1 | 2021 | 219 | 0.160 |
Why?
| Education, Nonprofessional | 1 | 2017 | 9 | 0.160 |
Why?
| Human Experimentation | 1 | 2017 | 11 | 0.160 |
Why?
| Sirtuin 1 | 1 | 2017 | 29 | 0.160 |
Why?
| Information Dissemination | 1 | 2019 | 104 | 0.160 |
Why?
| Teicoplanin | 1 | 2017 | 4 | 0.160 |
Why?
| Teaching Materials | 1 | 2017 | 35 | 0.150 |
Why?
| Sulfonamides | 1 | 2019 | 146 | 0.150 |
Why?
| 3' Untranslated Regions | 1 | 2017 | 57 | 0.150 |
Why?
| Mass Screening | 1 | 2021 | 370 | 0.150 |
Why?
| Treatment Outcome | 6 | 2019 | 5604 | 0.150 |
Why?
| Patient Participation | 1 | 2018 | 70 | 0.150 |
Why?
| Absorptiometry, Photon | 1 | 2018 | 174 | 0.150 |
Why?
| Retrospective Studies | 7 | 2012 | 6432 | 0.150 |
Why?
| Health Services Research | 1 | 2018 | 167 | 0.150 |
Why?
| Rural Population | 2 | 2021 | 600 | 0.150 |
Why?
| Substance Abuse Detection | 2 | 2022 | 92 | 0.150 |
Why?
| Reading | 1 | 2017 | 84 | 0.150 |
Why?
| Electrochemical Techniques | 1 | 2016 | 15 | 0.150 |
Why?
| Anthropometry | 2 | 2015 | 96 | 0.150 |
Why?
| Genetic Predisposition to Disease | 1 | 2020 | 570 | 0.140 |
Why?
| Comprehension | 1 | 2017 | 115 | 0.140 |
Why?
| Nuclear Proteins | 1 | 2018 | 252 | 0.140 |
Why?
| Saliva | 1 | 2016 | 63 | 0.140 |
Why?
| Vitamin A | 1 | 2016 | 18 | 0.140 |
Why?
| Liver Failure | 1 | 2016 | 27 | 0.140 |
Why?
| Amphetamine | 2 | 2013 | 42 | 0.140 |
Why?
| Nitric Oxide Synthase Type I | 2 | 2015 | 22 | 0.140 |
Why?
| Age Factors | 3 | 2015 | 1198 | 0.140 |
Why?
| Injections, Intravenous | 3 | 2012 | 148 | 0.140 |
Why?
| Point-of-Care Systems | 1 | 2016 | 70 | 0.140 |
Why?
| Blood Proteins | 2 | 2006 | 100 | 0.140 |
Why?
| Blood Pressure Monitors | 1 | 2015 | 10 | 0.140 |
Why?
| Taurodeoxycholic Acid | 1 | 2015 | 7 | 0.140 |
Why?
| Glycodeoxycholic Acid | 1 | 2015 | 7 | 0.140 |
Why?
| Glycochenodeoxycholic Acid | 1 | 2015 | 7 | 0.140 |
Why?
| Biomedical Research | 1 | 2019 | 240 | 0.140 |
Why?
| Keratin-8 | 1 | 2015 | 3 | 0.140 |
Why?
| Styrene | 1 | 2015 | 10 | 0.140 |
Why?
| Caffeine | 1 | 2016 | 77 | 0.130 |
Why?
| Guanidines | 1 | 2015 | 36 | 0.130 |
Why?
| Delayed-Action Preparations | 2 | 2012 | 50 | 0.130 |
Why?
| Prodrugs | 2 | 2012 | 33 | 0.130 |
Why?
| Solid Phase Extraction | 2 | 2013 | 12 | 0.130 |
Why?
| Bone Density | 1 | 2018 | 416 | 0.130 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2015 | 78 | 0.130 |
Why?
| Tablets | 3 | 2013 | 31 | 0.130 |
Why?
| Cross-Over Studies | 2 | 2012 | 250 | 0.130 |
Why?
| Immunity, Innate | 1 | 2016 | 114 | 0.130 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2014 | 2 | 0.130 |
Why?
| Administration, Intravenous | 3 | 2019 | 75 | 0.130 |
Why?
| Nitrates | 2 | 2011 | 49 | 0.130 |
Why?
| Environmental Pollutants | 1 | 2015 | 101 | 0.120 |
Why?
| Famotidine | 2 | 2005 | 11 | 0.120 |
Why?
| Discriminant Analysis | 1 | 2014 | 34 | 0.120 |
Why?
| Least-Squares Analysis | 1 | 2014 | 45 | 0.120 |
Why?
| Cells, Cultured | 4 | 2017 | 1737 | 0.120 |
Why?
| Fentanyl | 1 | 2014 | 34 | 0.120 |
Why?
| Superoxide Dismutase | 2 | 2011 | 125 | 0.120 |
Why?
| Urinalysis | 1 | 2014 | 50 | 0.120 |
Why?
| Wounds, Stab | 1 | 2013 | 8 | 0.120 |
Why?
| Cannabis | 2 | 2019 | 147 | 0.120 |
Why?
| Cyclosporine | 2 | 2011 | 66 | 0.120 |
Why?
| Basal Ganglia | 1 | 2013 | 26 | 0.120 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2012 | 434 | 0.120 |
Why?
| Benzoflavones | 1 | 2013 | 3 | 0.120 |
Why?
| Sulfaphenazole | 1 | 2013 | 4 | 0.120 |
Why?
| Neck Injuries | 1 | 2013 | 26 | 0.110 |
Why?
| Nonlinear Dynamics | 2 | 2012 | 21 | 0.110 |
Why?
| Self-Injurious Behavior | 1 | 2013 | 29 | 0.110 |
Why?
| Multidrug Resistance-Associated Proteins | 1 | 2012 | 19 | 0.110 |
Why?
| Mycophenolic Acid | 1 | 2012 | 17 | 0.110 |
Why?
| Kinetics | 4 | 2018 | 692 | 0.110 |
Why?
| Cohort Studies | 3 | 2019 | 1543 | 0.110 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2012 | 552 | 0.110 |
Why?
| Receptors, Phospholipase A2 | 1 | 2012 | 20 | 0.110 |
Why?
| Myoglobin | 1 | 2013 | 32 | 0.110 |
Why?
| Indicators and Reagents | 1 | 2012 | 42 | 0.110 |
Why?
| Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 26 | 0.110 |
Why?
| Neurotoxicity Syndromes | 1 | 2013 | 52 | 0.110 |
Why?
| Dinoprostone | 1 | 2012 | 55 | 0.110 |
Why?
| Flushing | 1 | 2012 | 5 | 0.110 |
Why?
| Piperacillin | 1 | 2012 | 25 | 0.110 |
Why?
| Permeability | 1 | 2012 | 87 | 0.110 |
Why?
| Seroepidemiologic Studies | 2 | 2022 | 50 | 0.110 |
Why?
| Immunoglobulin Fab Fragments | 1 | 2012 | 21 | 0.110 |
Why?
| Fasting | 1 | 2012 | 76 | 0.110 |
Why?
| Blood Specimen Collection | 1 | 2012 | 39 | 0.110 |
Why?
| Heart Septal Defects, Ventricular | 1 | 2012 | 36 | 0.110 |
Why?
| Lipopolysaccharides | 1 | 2013 | 199 | 0.110 |
Why?
| Metronidazole | 1 | 2012 | 30 | 0.100 |
Why?
| Erythema | 1 | 2012 | 49 | 0.100 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2012 | 122 | 0.100 |
Why?
| Exanthema | 1 | 2012 | 36 | 0.100 |
Why?
| T-Lymphocytes | 1 | 2014 | 373 | 0.100 |
Why?
| Insulin | 1 | 2014 | 510 | 0.100 |
Why?
| Ketamine | 1 | 2012 | 61 | 0.100 |
Why?
| Cardiopulmonary Bypass | 1 | 2012 | 97 | 0.100 |
Why?
| Pruritus | 1 | 2012 | 52 | 0.100 |
Why?
| Vancomycin | 1 | 2012 | 88 | 0.100 |
Why?
| Neutropenia | 1 | 2012 | 120 | 0.100 |
Why?
| Severity of Illness Index | 2 | 2012 | 1084 | 0.100 |
Why?
| Cellulitis | 1 | 2011 | 15 | 0.100 |
Why?
| Nitroimidazoles | 1 | 2011 | 17 | 0.100 |
Why?
| Anemia, Hemolytic | 1 | 2011 | 12 | 0.100 |
Why?
| Rhabdomyolysis | 1 | 2011 | 16 | 0.100 |
Why?
| Receptor, Cannabinoid, CB1 | 1 | 2012 | 128 | 0.100 |
Why?
| Sex Factors | 1 | 2014 | 767 | 0.100 |
Why?
| Neuroprotective Agents | 1 | 2012 | 125 | 0.100 |
Why?
| Hair | 1 | 2011 | 53 | 0.100 |
Why?
| Hypertension | 2 | 2015 | 564 | 0.100 |
Why?
| Anti-Inflammatory Agents | 1 | 2012 | 175 | 0.100 |
Why?
| Coloring Agents | 1 | 2010 | 84 | 0.100 |
Why?
| Kidney Transplantation | 1 | 2012 | 188 | 0.100 |
Why?
| Muscular Diseases | 1 | 2011 | 65 | 0.090 |
Why?
| Brain Injuries | 1 | 2012 | 183 | 0.090 |
Why?
| Immunoblotting | 1 | 2010 | 134 | 0.090 |
Why?
| Liver Circulation | 1 | 2010 | 27 | 0.090 |
Why?
| Play and Playthings | 1 | 2009 | 13 | 0.090 |
Why?
| Butylene Glycols | 1 | 2009 | 13 | 0.090 |
Why?
| Sodium Oxybate | 1 | 2009 | 11 | 0.090 |
Why?
| Interleukin-10 | 2 | 2012 | 107 | 0.090 |
Why?
| Coma | 1 | 2009 | 17 | 0.090 |
Why?
| Linear Models | 2 | 2012 | 309 | 0.090 |
Why?
| Databases as Topic | 1 | 2009 | 46 | 0.090 |
Why?
| Environmental Exposure | 1 | 2011 | 205 | 0.090 |
Why?
| Blood Pressure | 1 | 2012 | 587 | 0.090 |
Why?
| Immunosuppressive Agents | 1 | 2011 | 248 | 0.090 |
Why?
| Foreign Bodies | 1 | 2009 | 64 | 0.090 |
Why?
| Drug Compounding | 1 | 2008 | 28 | 0.080 |
Why?
| Analgesics, Opioid | 1 | 2014 | 501 | 0.080 |
Why?
| Kidney Diseases | 1 | 2012 | 293 | 0.080 |
Why?
| Blood Chemical Analysis | 1 | 2008 | 34 | 0.080 |
Why?
| Cesium | 1 | 2008 | 8 | 0.080 |
Why?
| Incidence | 1 | 2012 | 1082 | 0.080 |
Why?
| Probability | 1 | 2008 | 176 | 0.080 |
Why?
| Chlorides | 1 | 2008 | 58 | 0.080 |
Why?
| Chloroform | 1 | 2007 | 6 | 0.080 |
Why?
| Macrophages | 2 | 2017 | 405 | 0.080 |
Why?
| DNA | 1 | 2011 | 581 | 0.080 |
Why?
| Free Radical Scavengers | 2 | 2011 | 35 | 0.080 |
Why?
| Models, Statistical | 1 | 2009 | 259 | 0.080 |
Why?
| Magnetic Resonance Imaging | 2 | 2012 | 1604 | 0.080 |
Why?
| Infusions, Intravenous | 2 | 2023 | 231 | 0.080 |
Why?
| Sulfuric Acids | 1 | 2006 | 8 | 0.070 |
Why?
| Aerobiosis | 1 | 2006 | 16 | 0.070 |
Why?
| Electrocardiography | 1 | 2008 | 290 | 0.070 |
Why?
| Acute Kidney Injury | 1 | 2011 | 403 | 0.070 |
Why?
| Genotype | 3 | 2018 | 599 | 0.070 |
Why?
| Emergency Medicine | 1 | 2006 | 60 | 0.070 |
Why?
| Toxicity Tests | 1 | 2006 | 52 | 0.070 |
Why?
| Analysis of Variance | 1 | 2007 | 635 | 0.070 |
Why?
| Hepatitis C, Chronic | 2 | 2018 | 89 | 0.070 |
Why?
| Reproducibility of Results | 3 | 2015 | 1304 | 0.070 |
Why?
| Cell Nucleus | 1 | 2006 | 203 | 0.070 |
Why?
| Antioxidants | 2 | 2023 | 297 | 0.070 |
Why?
| Phosphorylation | 2 | 2019 | 614 | 0.060 |
Why?
| Metabolic Detoxication, Phase II | 2 | 2017 | 12 | 0.060 |
Why?
| Mitochondrial Membrane Transport Proteins | 1 | 2004 | 23 | 0.060 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 314 | 0.060 |
Why?
| Mice, Transgenic | 2 | 2018 | 656 | 0.060 |
Why?
| Kupffer Cells | 1 | 2003 | 18 | 0.060 |
Why?
| Glutathione Disulfide | 1 | 2003 | 45 | 0.060 |
Why?
| Single-Blind Method | 2 | 2015 | 120 | 0.060 |
Why?
| Models, Chemical | 2 | 2015 | 65 | 0.060 |
Why?
| Superoxides | 1 | 2003 | 61 | 0.060 |
Why?
| Alanine | 1 | 2023 | 44 | 0.060 |
Why?
| Pyruvic Acid | 1 | 2023 | 24 | 0.060 |
Why?
| Computer Simulation | 2 | 2017 | 332 | 0.060 |
Why?
| Omeprazole | 1 | 2003 | 17 | 0.060 |
Why?
| Child Abuse | 1 | 2006 | 170 | 0.060 |
Why?
| Mixed Function Oxygenases | 1 | 2003 | 24 | 0.060 |
Why?
| Injections, Intraperitoneal | 1 | 2003 | 59 | 0.060 |
Why?
| Risk Assessment | 1 | 2008 | 1361 | 0.060 |
Why?
| Immunoenzyme Techniques | 1 | 2003 | 165 | 0.060 |
Why?
| Safety | 1 | 2003 | 92 | 0.060 |
Why?
| Hydrogen Peroxide | 1 | 2003 | 142 | 0.060 |
Why?
| Radiographic Image Enhancement | 1 | 2003 | 32 | 0.060 |
Why?
| Prognosis | 3 | 2015 | 2118 | 0.060 |
Why?
| Tibial Fractures | 1 | 2003 | 34 | 0.060 |
Why?
| Oxygen | 1 | 2006 | 361 | 0.060 |
Why?
| Drug Interactions | 1 | 2003 | 206 | 0.060 |
Why?
| Molecular Structure | 2 | 2013 | 319 | 0.050 |
Why?
| Pediatrics | 1 | 2006 | 323 | 0.050 |
Why?
| Logistic Models | 2 | 2018 | 995 | 0.050 |
Why?
| Membrane Potential, Mitochondrial | 2 | 2015 | 48 | 0.050 |
Why?
| Hydroxylation | 2 | 2012 | 61 | 0.050 |
Why?
| Antibodies, Viral | 1 | 2022 | 124 | 0.050 |
Why?
| Glutamate Dehydrogenase | 1 | 2021 | 15 | 0.050 |
Why?
| Endothelium, Vascular | 1 | 2003 | 288 | 0.050 |
Why?
| Neoplasms | 1 | 2012 | 1316 | 0.050 |
Why?
| Death, Sudden, Cardiac | 1 | 2022 | 60 | 0.050 |
Why?
| Psychotropic Drugs | 1 | 2022 | 82 | 0.050 |
Why?
| Nitric Oxide | 1 | 2003 | 298 | 0.050 |
Why?
| Uncertainty | 1 | 2021 | 46 | 0.050 |
Why?
| Kidney Failure, Chronic | 1 | 2003 | 231 | 0.050 |
Why?
| Gestational Age | 2 | 2012 | 435 | 0.050 |
Why?
| Anti-Asthmatic Agents | 1 | 2020 | 31 | 0.050 |
Why?
| Australia | 1 | 2019 | 85 | 0.040 |
Why?
| Apoptosis | 1 | 2006 | 1300 | 0.040 |
Why?
| Decision Making | 1 | 2002 | 290 | 0.040 |
Why?
| Qualitative Research | 1 | 2021 | 331 | 0.040 |
Why?
| Drug Synergism | 1 | 2019 | 171 | 0.040 |
Why?
| Tissue Distribution | 2 | 2013 | 178 | 0.040 |
Why?
| Research Design | 1 | 2021 | 374 | 0.040 |
Why?
| Risk Factors | 3 | 2012 | 3935 | 0.040 |
Why?
| Hepatitis Viruses | 1 | 2018 | 2 | 0.040 |
Why?
| Metagenomics | 1 | 2018 | 38 | 0.040 |
Why?
| beta Catenin | 1 | 2019 | 102 | 0.040 |
Why?
| Mallory Bodies | 1 | 2018 | 1 | 0.040 |
Why?
| Drug Dosage Calculations | 1 | 2018 | 11 | 0.040 |
Why?
| Acute-Phase Reaction | 1 | 2018 | 9 | 0.040 |
Why?
| Ethics, Research | 1 | 2017 | 41 | 0.040 |
Why?
| DNA, Viral | 1 | 2018 | 142 | 0.040 |
Why?
| RNA, Viral | 1 | 2018 | 141 | 0.040 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2018 | 85 | 0.040 |
Why?
| Metabolic Detoxication, Phase I | 1 | 2017 | 11 | 0.040 |
Why?
| Gas Chromatography-Mass Spectrometry | 2 | 2011 | 70 | 0.040 |
Why?
| Metabolic Networks and Pathways | 1 | 2018 | 104 | 0.040 |
Why?
| Gene Frequency | 1 | 2017 | 120 | 0.040 |
Why?
| MAP Kinase Signaling System | 1 | 2018 | 133 | 0.040 |
Why?
| Glucuronides | 1 | 2017 | 57 | 0.040 |
Why?
| Plant Extracts | 1 | 2019 | 193 | 0.040 |
Why?
| Communication | 1 | 2019 | 273 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 206 | 0.040 |
Why?
| Rats | 2 | 2014 | 3415 | 0.040 |
Why?
| Residence Characteristics | 1 | 2017 | 166 | 0.040 |
Why?
| Liver Diseases, Alcoholic | 1 | 2016 | 35 | 0.030 |
Why?
| Oscillometry | 1 | 2015 | 9 | 0.030 |
Why?
| NAD | 1 | 2015 | 46 | 0.030 |
Why?
| Diastole | 1 | 2015 | 79 | 0.030 |
Why?
| Sex Characteristics | 1 | 2017 | 214 | 0.030 |
Why?
| Systole | 1 | 2015 | 80 | 0.030 |
Why?
| Arm | 1 | 2015 | 52 | 0.030 |
Why?
| Binding, Competitive | 1 | 2015 | 113 | 0.030 |
Why?
| Observer Variation | 1 | 2015 | 138 | 0.030 |
Why?
| Health Literacy | 1 | 2017 | 141 | 0.030 |
Why?
| Registries | 1 | 2018 | 553 | 0.030 |
Why?
| Patient Safety | 1 | 2016 | 121 | 0.030 |
Why?
| Substrate Specificity | 1 | 2015 | 209 | 0.030 |
Why?
| Clinical Protocols | 1 | 2015 | 122 | 0.030 |
Why?
| Suramin | 1 | 2014 | 14 | 0.030 |
Why?
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2014 | 3 | 0.030 |
Why?
| Fas Ligand Protein | 1 | 2014 | 21 | 0.030 |
Why?
| Antigens, Ly | 1 | 2014 | 10 | 0.030 |
Why?
| Islets of Langerhans | 1 | 2014 | 23 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 206 | 0.030 |
Why?
| Glucose Tolerance Test | 1 | 2014 | 67 | 0.030 |
Why?
| Oxygen Consumption | 1 | 2015 | 223 | 0.030 |
Why?
| Cell Proliferation | 1 | 2019 | 1096 | 0.030 |
Why?
| Gene Silencing | 1 | 2014 | 129 | 0.030 |
Why?
| Algorithms | 1 | 2018 | 697 | 0.030 |
Why?
| Biological Availability | 2 | 2005 | 131 | 0.030 |
Why?
| Paper | 1 | 2013 | 16 | 0.030 |
Why?
| Thiazolidinediones | 1 | 2014 | 95 | 0.030 |
Why?
| Capsules | 1 | 2013 | 34 | 0.030 |
Why?
| Pentanones | 1 | 2013 | 9 | 0.030 |
Why?
| Methylamines | 1 | 2013 | 15 | 0.030 |
Why?
| Powders | 1 | 2013 | 32 | 0.030 |
Why?
| Glutathione Transferase | 1 | 2014 | 178 | 0.030 |
Why?
| Brain | 2 | 2012 | 1387 | 0.030 |
Why?
| Ethanol | 1 | 2016 | 322 | 0.030 |
Why?
| Body Temperature Regulation | 1 | 2013 | 35 | 0.030 |
Why?
| Hallucinogens | 1 | 2013 | 60 | 0.030 |
Why?
| Heterozygote | 1 | 2012 | 96 | 0.030 |
Why?
| Benzodioxoles | 1 | 2013 | 56 | 0.030 |
Why?
| Fatal Outcome | 1 | 2013 | 225 | 0.030 |
Why?
| Drug Resistance | 1 | 2012 | 74 | 0.030 |
Why?
| Amine Oxidase (Copper-Containing) | 1 | 2012 | 5 | 0.030 |
Why?
| Placebo Effect | 1 | 2012 | 19 | 0.030 |
Why?
| Interleukin-3 | 1 | 2012 | 13 | 0.030 |
Why?
| Intention to Treat Analysis | 1 | 2012 | 28 | 0.030 |
Why?
| Pyrans | 1 | 2012 | 27 | 0.030 |
Why?
| Calcitonin Gene-Related Peptide | 1 | 2012 | 24 | 0.030 |
Why?
| Prescription Drugs | 1 | 2012 | 35 | 0.030 |
Why?
| Histamine | 1 | 2012 | 28 | 0.030 |
Why?
| Pyrrolidines | 1 | 2013 | 88 | 0.030 |
Why?
| Calcitonin | 1 | 2012 | 38 | 0.030 |
Why?
| Insurance, Health, Reimbursement | 1 | 2012 | 24 | 0.030 |
Why?
| Protein Precursors | 1 | 2012 | 47 | 0.030 |
Why?
| Cell Survival | 1 | 2014 | 657 | 0.030 |
Why?
| Population | 1 | 2012 | 10 | 0.030 |
Why?
| Fever | 1 | 2013 | 129 | 0.030 |
Why?
| Spectroscopy, Near-Infrared | 1 | 2012 | 62 | 0.030 |
Why?
| Disease Progression | 1 | 2015 | 913 | 0.030 |
Why?
| Office Visits | 1 | 2012 | 49 | 0.030 |
Why?
| Dopamine | 1 | 2013 | 190 | 0.030 |
Why?
| Glucose | 1 | 2014 | 366 | 0.030 |
Why?
| Expectorants | 1 | 2011 | 14 | 0.030 |
Why?
| Genetic Association Studies | 1 | 2012 | 136 | 0.030 |
Why?
| Hyperthermia, Induced | 1 | 2013 | 107 | 0.030 |
Why?
| Ligands | 1 | 2012 | 230 | 0.030 |
Why?
| Glucuronic Acid | 1 | 2011 | 9 | 0.030 |
Why?
| Risk | 1 | 2012 | 343 | 0.030 |
Why?
| Deuterium | 1 | 2011 | 41 | 0.030 |
Why?
| Creatinine | 1 | 2012 | 169 | 0.030 |
Why?
| Microsomes | 1 | 2011 | 45 | 0.030 |
Why?
| Central Nervous System | 1 | 2012 | 85 | 0.030 |
Why?
| Reference Standards | 1 | 2011 | 63 | 0.030 |
Why?
| Statistics as Topic | 1 | 2011 | 103 | 0.030 |
Why?
| Monte Carlo Method | 1 | 2012 | 99 | 0.030 |
Why?
| Birth Weight | 1 | 2012 | 126 | 0.030 |
Why?
| ROC Curve | 1 | 2012 | 259 | 0.030 |
Why?
| Syndrome | 1 | 2012 | 252 | 0.030 |
Why?
| Forensic Toxicology | 1 | 2011 | 5 | 0.030 |
Why?
| Hair Color | 1 | 2011 | 10 | 0.020 |
Why?
| Muscular Dystrophies | 1 | 2011 | 16 | 0.020 |
Why?
| Spinal Muscular Atrophies of Childhood | 1 | 2011 | 8 | 0.020 |
Why?
| Glucuronidase | 1 | 2011 | 48 | 0.020 |
Why?
| Cytoplasm | 1 | 2011 | 108 | 0.020 |
Why?
| Crime | 1 | 2011 | 29 | 0.020 |
Why?
| Transaminases | 1 | 2011 | 14 | 0.020 |
Why?
| C-Reactive Protein | 1 | 2012 | 159 | 0.020 |
Why?
| Protein Isoforms | 1 | 2011 | 124 | 0.020 |
Why?
| Forecasting | 1 | 2012 | 161 | 0.020 |
Why?
| Staining and Labeling | 1 | 2011 | 106 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2012 | 643 | 0.020 |
Why?
| Bilirubin | 1 | 2011 | 49 | 0.020 |
Why?
| Intensive Care Units | 1 | 2012 | 231 | 0.020 |
Why?
| Child Development | 1 | 2012 | 204 | 0.020 |
Why?
| Double-Blind Method | 1 | 2012 | 742 | 0.020 |
Why?
| Blotting, Western | 1 | 2011 | 683 | 0.020 |
Why?
| Suction | 1 | 2009 | 22 | 0.020 |
Why?
| Body Mass Index | 1 | 2013 | 713 | 0.020 |
Why?
| Intensive Care Units, Pediatric | 1 | 2011 | 186 | 0.020 |
Why?
| Intestines | 1 | 2011 | 204 | 0.020 |
Why?
| Intestinal Mucosa | 1 | 2011 | 259 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 2013 | 1663 | 0.020 |
Why?
| Eating | 1 | 2009 | 155 | 0.020 |
Why?
| Alcohol Drinking | 1 | 2011 | 259 | 0.020 |
Why?
| Survival Rate | 1 | 2011 | 951 | 0.020 |
Why?
| Clinical Trials as Topic | 1 | 2011 | 490 | 0.020 |
Why?
| Alcoholism | 1 | 2011 | 249 | 0.020 |
Why?
| Kidney | 1 | 2013 | 820 | 0.020 |
Why?
| Nitric Oxide Synthase | 1 | 2007 | 102 | 0.020 |
Why?
| Muscle, Skeletal | 1 | 2013 | 847 | 0.020 |
Why?
| Carcinoma, Hepatocellular | 1 | 2008 | 203 | 0.020 |
Why?
| Liver Neoplasms | 1 | 2008 | 352 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2009 | 2387 | 0.010 |
Why?
| Electrophoresis, Gel, Pulsed-Field | 1 | 2003 | 28 | 0.010 |
Why?
| Specialization | 1 | 2003 | 46 | 0.010 |
Why?
| Medicine | 1 | 2003 | 58 | 0.010 |
Why?
| Endopeptidases | 1 | 2002 | 75 | 0.010 |
Why?
| Polymerase Chain Reaction | 1 | 2003 | 531 | 0.010 |
Why?
|
|
James's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|